Entia Biosciences Completes Parkinson’s Disease Study

Business & Professional Services

Share Tweet

Entia Biosciences Completes Parkinson’s Disease Study

SHERWOOD, OR, August 26, 2013 -(ACCESSWIRE)- Entia Biosciences (OTCQB: ERGO), a food science biotechnology company and emerging leader in the field of Nutrigenomics, has completed a Parkinson's disease study in the Neurochemistry Laboratory of Dr. Jack Rogers at Massachusetts General Hospital, Charlestown, MA. The results from the study have been submitted to a peer-reviewed medical journal and the paper is entitled: "Improved Grip Strength and Alpha-Synuclein Levels in a Parkinson's disease Mouse Model Using the Novel Antioxidant Medical Food ErgoD2."

The Neurochemistry Laboratory at Massachusetts General Hospital designed a study to evaluate whether a standard diet that was supplemented with ErgoD2, a natural antioxidant therapy, had the ability to modify symptoms and blood and brain biomarkers associated with Parkinson's disease. The medical food diet included a composition enriched in levels of L-Ergothioneine and Vitamin D2 (ErgoD2). This diet was found to statistically improve grip strength in a well-known transgenic mouse model of Parkinson's disease. Moreover, the improvement in grip strength correlated with the suppression of the alpha-synuclein biomarker in the midbrain after four months of using the natural dietary regimen.

"This study highlights the therapeutic potential of a medicinal food, ErgoD2, comprised of the potent antioxidants, L-Ergothioneine and Vitamin D2, in Parkinson's disease" stated Marvin S. Hausman MD, CEO, Entia Biosciences, Inc. "We are elated that our four years of hard work on natural antioxidant models has led to the development of ErgoD2, a novel compound that has the potential to provide relevant clinical therapy. Most available treatments in Parkinson's disease as well as other neurodegenerative diseases are based on drugs with side effects that only provide symptomatic relief. This study represents a unique model, based upon a specific, natural and safe diet that has the potential to modify a devastating disease. Entia intends to launch a clinical study in humans to confirm these findings."

About Entia Biosciences, Inc.

Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics.  The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2012 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially.  Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For more information, please visit our web sites at www.entiabio.com or contact:

Devin Andres

Chief Operating Officer

Entia Biosciences, Inc.

13565 SW Tualatin-Sherwood Rd Sherwood, OR, 97140

Phone: 503-334-3575

Email: [email protected]

SOURCE: Entia Biosciences, Inc.